期刊
ADIPOCYTE
卷 10, 期 1, 页码 446-455出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21623945.2021.1979277
关键词
Dapagliflozin; high-fat diet; hepatic steatosis; adiposity; browning
资金
- National Natural Science Foundation of China [81273878]
Dapagliflozin has shown potential benefits in promoting fat utilization, improving adipose tissue, and inhibiting fat accumulation and hepatic steatosis in obese mice on a high-fat diet, suggesting its potential clinical application in preventing obesity and related metabolic diseases.
With the increasing obesity prevalence, the rates of obesity-related diseases, including type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases, have increased dramatically. Dapagliflozin, one of the sodium glucose cotransporter inhibitors, not only exerts hypoglycaemic effects through increasing urinary glucose excretion but alsoreprograms the metabolic system, leading to benefits in metabolic and cardiovascular diseases. In this study, preestablished obese mice on a high-fat diet were given dapagliflozin by gavage for fourweeks. It showed that dapagliflozin can enhance fat utilization and browning of adipose tissue and improve local oxidative stress, thus inhibiting fat accumulation and hepatic steatosis without disturbance in body weight or plasma glycolipid level. Overall, our study highlights the potential clinical application of SGLT2 inhibition in the prevention of obesity and related metabolic diseases, such as insulin resistance, NAFLD, and diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据